Study Assessing Tolerability and Safety of AFFITOPE® PD03A in Patients With Early Parkinson's Disease (AFF011)

A Randomized, Placebo-controlled, Parallel Group, Patient-blinded, Multi-center, Phase I Pilot Study to Assess Tolerability and Safety of Two Doses of AFFITOPE® PD03A Formulated With Adjuvant to Patients With Early Parkinson's Disease

Study AFF011 is a randomized controlled parallel Group phase I study to investigate the safety and tolerability of two doses of the vaccine AFFITOPE® PD03A given to patients with early Parkinson's disease.

In total 36 patients will be enrolled in 3 independent groups (2 treatment groups, 1 Placebo group), each consisting of 12 patients. The patients will be randomized to either receive 15µg or 75µg AFFITOPE® PD03A formulated with adjuvant or the reference substance without active component (Placebo). Over a study duration of 52 weeks, the study participants receive 4 injections as basic immunization in a 4-weekly interval and 1 boost immunization 36 weeks after the first injection. Male and female patients aged 45 to 70 years can participate in the trial. 2 study sites in Austria (Innsbruck and Vienna) will be involved.

AFF011 is part of a project SYMPATH funded by the European Commission (FP7-HEALTH-2013-INNOVATION-1 project; N° HEALTH-F4-2013-602999).

Study Overview

• Status: Completed
• Conditions: Parkinson Disease; Neurodegenerative Diseases
• Intervention / Treatment: Biological: Low dose AFFITOPE® PD03A + Adjuvant; Biological: High dose AFFITOPE® PD03A + Adjuvant; Biological: Adjuvant without active component

• Study Type: Interventional
• Enrollment (Actual): 36
• Phase: Phase 1

Contacts and Locations

Study Locations

• Austria
  • Innsbruck, Austria, 6020
    • Medical University Innsbruck, Department of Neurology
  • Vienna, Austria, 1080
    • Studienzentrum der PROSENEX, AmbulatoriumbetriebsgesmbH an der Confraternität -Privatklinik Josefstadt

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 41 years to 66 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Individuals with IPS diagnosed for less than 4 years and who present in Hoehn & Yahr Stages I/II and fulfill the United Kingdom Parkinson's Disease Society Brain Bank Criteria
• The result of a DAT-SPECT and MRI examination of the patient's brain has to be consistent with the diagnosis of PD
• Written Informed Consent Form signed and dated by the patient
• Age between 45 and 70
• Female patients of childbearing potential are eligible if they use a medically accepted contraceptive method
• A potential participant treated with conventional PD therapies must be on stable doses for at least 3 months prior to Visit 0 and during the entire trial period and must be a stable responder
• Accepted PD medications include the following: levodopa (alone or in combination with benserazide, carbidopa), Catechol-O-methyltransferase inhibitors (entacapone, tolcapone), amantadine, non-ergot dopamine agonists (pramipexol, ropinirol, rotigotine), monoamine oxidase-B inhibitors (rasagiline, selegiline) and anticholinergic medication
• A potential participant has to be on stable doses of all medications he/she is taking because of consisting illnesses according to medical history (except PD therapies, these will be recorded separately) for at least 30 days prior to Visit 0, if considered relevant by the PI
• Upon PI's opinion, no visual or auditory impairments that would reduce the patients' ability to complete study questionnaires or be unable to receive instructions for these

Exclusion Criteria:

• Pregnant women
• Sexually active women of childbearing potential who are not using a medically accepted birth control method throughout the study
• Participation in another clinical trial within 3 months before Visit 0
• History of questionable compliance to visit schedule; patients not expected to complete the clinical trial
• Presence or history of allergy to components of the vaccine, if considered relevant by the PI
• Contraindication for MRI imaging such as metallic endoprosthesis or stent implantation in the last 6 months or allergy to MRI contrast agent
• Contraindication for DAT-SPECT
• Contraindication for lumbar puncture such as anticoagulation
• Dementia
• History and/or presence of autoimmune disease, if considered relevant by the PI
• Recent (≤3 years since last specific treatment) history of cancer (Exceptions: basal cell carcinoma, intraepithelial cervical neoplasia)
• Active infectious disease (e.g., Hepatitis B, C)
• Presence and/or history of Immunodeficiency (e.g., HIV)
• Significant systemic illness (e.g., chronic renal failure, chronic liver disease, poorly controlled diabetes, poorly controlled congestive heart failure, other deficiencies), if considered relevant by the PI
• History of significant psychiatric illness such as schizophrenia, bipolar affective disorder or psychotic depression
• Parkinson-like disease secondary to drug therapy side effects (e.g., due to exposure to medications that deplete dopamine [reserpine, tetrabenazine] or block dopamine receptors [neuroleptics, antiemetics]
• Parkinson-plus syndromes (e.g. MSA, PSP)
• Heredodegenerative disorders
• Alcoholism or substance abuse within the past year (alcohol or drug intoxication)
• Prior and/or current treatment with experimental immunotherapeutics including intravenous immunoglobulin
• Prior and/or current treatment with immunosuppressive drugs
• Change in dose of standard treatments for PD within 3 months prior to Visit 0
• Change in dose of previous and current medications which the patient is taking because of consisting illnesses according medical history (except PD therapies, these will be recorded separately) within the last 30 days prior to Visit 0, if clinically relevant
• Treatment with deep brain stimulation
• Venous status rendering it impossible to place an i.v. access
• L-Dopa related motor complications (response fluctuations and/or dyskinesia)
• Evidence for genetic forms of PD: leucine-rich repeat kinase 2 and Parkin

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Low dose AFFITOPE® PD03A + Adjuvant; 4 injections of 15µg AFFITOPE® PD03A/ adjuvanted, once every 4 weeks 1 boost immunization 36 weeks after first injection	Biological: Low dose AFFITOPE® PD03A + Adjuvant; s.c. injection
Experimental: High dose AFFITOPE® PD03A + Adjuvant; 4 injections of 75µg AFFITOPE® PD03A/ adjuvanted, once every 4 weeks 1 boost immunization 36 weeks after first injection	Biological: High dose AFFITOPE® PD03A + Adjuvant; s.c. injection
Placebo Comparator: Adjuvant without active component; 4 injections of Placebo once every 4 weeks 1 administration 36 weeks after first injection	Biological: Adjuvant without active component; s.c. injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of patients who withdraw due to Adverse Events (AEs)	The withdrawal criteria (continuation decision) in regards to the number of patients who withdraw due to AEs as well as the reason for withdrawal will be evaluated.	12 months
Occurrence of Adverse Events and Serious Adverse Events	Evaluation of Adverse Events and Serious Adverse Events in regards to autoimmune reactions	12 months
New findings or Change in pre-existing findings assessed in physical and neurological examinations over time (study period)		12 months
Change in vital signs and Body mass over time (study period)	The Evaluation of vital signs includes the changes in blood pressure, heart rate, respiratory rate and Body temperature over time (measured at each visit).	12 months
Safety related Evaluation of MRI results of patients' brain after visit 5 and visit 8 compared to baseline	MRI safety measures will e.g. include the occurrence of inflammatory reactions (meningoencephalitis), new/changed hemorrhages and lacunar infarcts.	12 months
Clinical significance/changes in laboratory parameters over time (study period)	Laboratory assessment includes hematology, biochemistry, coagulation, serology and urinanalysis.	12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Immunological activity of AFFITOPE® vaccine PD03A	Titer of vaccination induced antibodies directed towards vaccine components, alpha- and beta synuclein	12 months
Change in motor symptoms at visit 8 and visit 11 compared to baseline	Change in motor symptoms: MDS Unified Parkinson's Disease Rating Scale (UPDRS) II and III	12 months
Change in non-motor symptoms at visit 8 and visit 11 compared to baseline	Change in non-motor symptoms: PDQ-39 (Parkinson's Disease Quality of Life-39)/PD non-motor symptom score, MDS UPDRS I (Movement Disorder Society Unified Parkinson's Disease Rating scale), cognitive test battery, HAM-D (Hamilton Depression Rating Scale)	12 months

Collaborators and Investigators

• Sponsor: Affiris AG
• Collaborators: Medical University Innsbruck; Forschungszentrum Juelich; PROSENEX AmbulatoriumbetriebsGMBH
• Investigators: Principal Investigator: Werner Poewe, MD, Medical University Innsbruck, Department of Neurology, Innsbruck 6020, Austria

Study record dates

Study Major Dates

• Study Start: December 1, 2014
• Primary Completion (Actual): August 1, 2016
• Study Completion (Actual): August 1, 2016

Study Registration Dates

• First Submitted: September 4, 2014
• First Submitted That Met QC Criteria: October 14, 2014
• First Posted (Estimate): October 17, 2014

Study Record Updates

• Last Update Posted (Estimate): October 31, 2016
• Last Update Submitted That Met QC Criteria: October 28, 2016
• Last Verified: October 1, 2016

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Parkinsonian Disorders; Basal Ganglia Diseases; Movement Disorders; Synucleinopathies; Parkinson Disease; Neurodegenerative Diseases
• Other Study ID Numbers: AFFiRiS 011; 2014-000568-16 (EudraCT Number)